Cover Image
Market Research Report
Product code 
1046630

Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

Published: | KBV Research | 193 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027
Published: November 30, 2021
KBV Research
Content info: 193 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Filgrastim Market size is expected to reach $953.4 million by 2027, rising at a market growth of 8.0% CAGR during the forecast period.

Filgrastim refers to the recombinant DNA-derived granulocyte colony-stimulating factor (G-CSF), which is generally utilized to cure low blood neutrophils. It is especially used in cases wherein lukapheresis is linked with rising white blood cells. In addition, there are some side effects of using filgrastim that include chest pain, hair loss, joint discomfort, and vomiting.

Filgrastim injections are utilized in the process of curing neutropenia which is a condition of having low white blood cells that can be caused by cancer medicines. This injection is a man-made form of a substance, which is naturally created in a person's body called a colony-stimulating factor. In addition, filgrastim assists the bone marrow to develop new white blood cells.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted the workflow of the healthcare industry around the world. The disruption in the supply chain of various goods and the temporary ban on manufacturing units had a negative impact on the filgrastim market. The pandemic has increased the pressure on healthcare systems of the world. More staff and resources were reassigned to treat COVID patients who were earlier taking care of patients with a different disease. A decline in recruitment to the trials and obstruct in the planned release of the latest oncology studies would affect the filgrastim market. There are certain biosimilar developers who have also entered the market of non-biosimilar products for the development stage to find a treatment for the SAR-COV-2 virus. There are certain filgrastim biosimilars that are also utilized to cure COVID-19 infected patients.

Market Growth Factors:

Increase in the aging population

There is an increase in the geriatric population across various nations of the world, which would fuel the demand for biopharmaceuticals like filgrastim biosimilars to cure the side effects caused by the treatment of numerous chronic diseases like cancer. People with the age of 65 years have surged around the world along with that age-related chronic ailments have also increased. These aged people are more vulnerable to chronic diseases.

Growing cases of chronic diseases

Chronic disease refers to a group of diseases including cardiovascular diseases, diabetes, cancer, and others. There is a rise in the number of chronic diseases among the population across the globe. Factors such as sedentary lifestyle, unhealthy diet, and consumption of tobacco are responsible for chronic diseases. Cancer is one of the top reasons behind death across the world which caused approximately 10 million deaths in 2020. Among the total number of deaths due to cancer, approx. 70% of deaths were reported in low- and middle-income countries.

Market Restraining Factors:

Stringent government regulations and policies

Pharmaceutical companies that are developing biosimilars like filgrastim face a major challenge in the approval process of their products. Different countries have a different process of approval for any medicine, treatment, vaccine, and medical device; however, these approval procedures are difficult to follow. It is due to the various regulations and evidence required to prove the efficacy and safety of that product.

Drug Type Outlook

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Among both, the biosimilars segment is estimated to display a promising CAGR owing to the easy availability and low cost in emerging nations.

Indication Outlook

Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Among these, the chemotherapy-induced neutropenia segment acquired the highest share in the filgrastim market in 2020 and is anticipated to continue its dominance over the forecast period.

Distribution Channel Outlook

By distribution channel, the filgrastim market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Among all, the hospital pharmacies market is anticipated to witness a substantial growth during the forecast period owing to the increasing demand for filgrastim in hospitals around the world.

Regional Outlook

Region-wise, the filgrastim market is analyzed across North America, Europe, Asia Pacific, and LAMEA. North America emerged as the leading region in the filgrastim market in 2020 with the highest market share and is estimated to maintain its dominance during the forecast period. It is owing to the developed healthcare infrastructure, growing prevalence of infectious diseases, supportive reimbursement policies, and accessibility of research grants & funding.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksoz Group

Strategies Deployed in Filgrastim Market

Nov-2021: Apobiologix, a subsidiary of Apotex introduced Bambevi. This product is utilized in combination with chemotherapy to cure specific kinds of colorectal, brain, lung, and ovarian cancer. This launch would expand the Apobiologix portfolio to make sure constant support of patient requirements.

Jun-2021: Kyowa Kirin came into an agreement with Amgen, an American multinational biopharmaceutical company. This agreement aimed to develop and market KHK4083, Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody.

Jun-2020: Pfizer got the approval for NYVEPRIA, a biosimilar to Neulasta from the US Food and Drug Administration (FDA). This approval helps in enabling cost savings and provides better access to a crucial treatment option.

Nov-2019: Novartis unveiled Sandoz's pegfilgrastim biosimilar, Ziextenzo, in the United States. Ziextenzo is used to decrease the duration of neutropenia and incidence of febrile neutropenia in adult patients cured with cytotoxic (anti-cancer) chemotherapy for malignancy with the exception of chronic myeloid leukemia and myelodysplastic syndromes.

Mar-2019: Apobiologix, a division of Apotex unveiled its pegfilgrastim biosimilar, Lapelga, in Canada. By availing Lapelga and Grastofil in Canada, patients can get better access to innovative, affordable, and effective biological drugs, along with providing substantial cost savings to the healthcare system.

Mar-2019: Pfizer received approval from the United States (U.S.) Food and Drug Administration (FDA) for TRAZIMERA, a biosimilar to Herceptin. This product is used in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Aug-2018: Teva Pharmaceutical received approval from the U.S. FDA for Granix (tbo-filgrastim) Injection. This injection is used for a new vial presentation and indication in pediatric patients one month and older. In addition, this pediatric indication and vial presentation of Granix would expand the product line of treatment options, which could provide advantages for patients and healthcare providers.

Jul-2018: Dr. Reddy's Laboratories released Hervycta, a biosimilar of Roche's Herceptin, in India. This product is indicated for the treatment of HER2-positive cancers, which would benefit women in India who have HER2-positive breast cancer and are required access to affordable, high-quality and innovative medicines.

Jul-2018: Pfizer got approval from the US FDA for NIVESTYM, a biosimilar to Neupogen. This product is for all eligible indications of the reference product. The FDA approval helped the company to expand access to critical treatment options for patients with neutropenia.

Dec-2017: Teva Pharmaceutical Industries got approval from South Africa's Medicines Control Council (MCC) for the country's first non-originator biological, filgrastim. This filgrastim is recommended as an important treatment for chemotherapy-induced febrile neutropenia and peripheral blood stem cell harvesting in autologous stem cell harvesting in haematological malignancies.

May-2017: Dr. Reddy's Laboratories entered into an agreement with GE Healthcare, a subsidiary of American multinational conglomerate General Electric. Under this agreement, Dr. Reddy's Laboratories installed FlexFactory, a manufacturing platform by GE Healthcare, to expand biologics production capabilities at its facility in Hyderabad, India.

Scope of the Study

Market Segments covered in the Report:

By Drug Type

  • Biosimilar and
  • Biologic

By Indication

  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksoz Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Filgrastim Market, by Drug Type
    • 1.4.2 Global Filgrastim Market, by Indication
    • 1.4.3 Global Filgrastim Market, by Distribution Channel
    • 1.4.4 Global Filgrastim Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Filgrastim Market by Drug Type

  • 3.1 Global Biosimilar Market by Region
  • 3.2 Global Biologic Market by Region

Chapter 4. Global Filgrastim Market by Indication

  • 4.1 Global Chemotherapy induced Neutropenia Market by Region
  • 4.2 Global Chronic Neutropenia Market by Region
  • 4.3 Global Other Indications Market by Region

Chapter 5. Global Filgrastim Market by Distribution Channel

  • 5.1 Global Hospital Pharmacies Market by Region
  • 5.2 Global Retail Pharmacies Market by Region
  • 5.3 Global Online Pharmacies Market by Region

Chapter 6. Global Filgrastim Market by Region

  • 6.1 North America Filgrastim Market
    • 6.1.1 North America Filgrastim Market by Drug Type
      • 6.1.1.1 North America Biosimilar Market by Country
      • 6.1.1.2 North America Biologic Market by Country
    • 6.1.2 North America Filgrastim Market by Indication
      • 6.1.2.1 North America Chemotherapy induced Neutropenia Market by Country
      • 6.1.2.2 North America Chronic Neutropenia Market by Country
      • 6.1.2.3 North America Other Indications Market by Country
    • 6.1.3 North America Filgrastim Market by Distribution Channel
      • 6.1.3.1 North America Hospital Pharmacies Market by Country
      • 6.1.3.2 North America Retail Pharmacies Market by Country
      • 6.1.3.3 North America Online Pharmacies Market by Country
    • 6.1.4 North America Filgrastim Market by Country
      • 6.1.4.1 US Filgrastim Market
        • 6.1.4.1.1 US Filgrastim Market by Drug Type
        • 6.1.4.1.2 US Filgrastim Market by Indication
        • 6.1.4.1.3 US Filgrastim Market by Distribution Channel
      • 6.1.4.2 Canada Filgrastim Market
        • 6.1.4.2.1 Canada Filgrastim Market by Drug Type
        • 6.1.4.2.2 Canada Filgrastim Market by Indication
        • 6.1.4.2.3 Canada Filgrastim Market by Distribution Channel
      • 6.1.4.3 Mexico Filgrastim Market
        • 6.1.4.3.1 Mexico Filgrastim Market by Drug Type
        • 6.1.4.3.2 Mexico Filgrastim Market by Indication
        • 6.1.4.3.3 Mexico Filgrastim Market by Distribution Channel
      • 6.1.4.4 Rest of North America Filgrastim Market
        • 6.1.4.4.1 Rest of North America Filgrastim Market by Drug Type
        • 6.1.4.4.2 Rest of North America Filgrastim Market by Indication
        • 6.1.4.4.3 Rest of North America Filgrastim Market by Distribution Channel
  • 6.2 Europe Filgrastim Market
    • 6.2.1 Europe Filgrastim Market by Drug Type
      • 6.2.1.1 Europe Biosimilar Market by Country
      • 6.2.1.2 Europe Biologic Market by Country
    • 6.2.2 Europe Filgrastim Market by Indication
      • 6.2.2.1 Europe Chemotherapy induced Neutropenia Market by Country
      • 6.2.2.2 Europe Chronic Neutropenia Market by Country
      • 6.2.2.3 Europe Other Indications Market by Country
    • 6.2.3 Europe Filgrastim Market by Distribution Channel
      • 6.2.3.1 Europe Hospital Pharmacies Market by Country
      • 6.2.3.2 Europe Retail Pharmacies Market by Country
      • 6.2.3.3 Europe Online Pharmacies Market by Country
    • 6.2.4 Europe Filgrastim Market by Country
      • 6.2.4.1 Germany Filgrastim Market
        • 6.2.4.1.1 Germany Filgrastim Market by Drug Type
        • 6.2.4.1.2 Germany Filgrastim Market by Indication
        • 6.2.4.1.3 Germany Filgrastim Market by Distribution Channel
      • 6.2.4.2 UK Filgrastim Market
        • 6.2.4.2.1 UK Filgrastim Market by Drug Type
        • 6.2.4.2.2 UK Filgrastim Market by Indication
        • 6.2.4.2.3 UK Filgrastim Market by Distribution Channel
      • 6.2.4.3 France Filgrastim Market
        • 6.2.4.3.1 France Filgrastim Market by Drug Type
        • 6.2.4.3.2 France Filgrastim Market by Indication
        • 6.2.4.3.3 France Filgrastim Market by Distribution Channel
      • 6.2.4.4 Russia Filgrastim Market
        • 6.2.4.4.1 Russia Filgrastim Market by Drug Type
        • 6.2.4.4.2 Russia Filgrastim Market by Indication
        • 6.2.4.4.3 Russia Filgrastim Market by Distribution Channel
      • 6.2.4.5 Spain Filgrastim Market
        • 6.2.4.5.1 Spain Filgrastim Market by Drug Type
        • 6.2.4.5.2 Spain Filgrastim Market by Indication
        • 6.2.4.5.3 Spain Filgrastim Market by Distribution Channel
      • 6.2.4.6 Italy Filgrastim Market
        • 6.2.4.6.1 Italy Filgrastim Market by Drug Type
        • 6.2.4.6.2 Italy Filgrastim Market by Indication
        • 6.2.4.6.3 Italy Filgrastim Market by Distribution Channel
      • 6.2.4.7 Rest of Europe Filgrastim Market
        • 6.2.4.7.1 Rest of Europe Filgrastim Market by Drug Type
        • 6.2.4.7.2 Rest of Europe Filgrastim Market by Indication
        • 6.2.4.7.3 Rest of Europe Filgrastim Market by Distribution Channel
  • 6.3 Asia Pacific Filgrastim Market
    • 6.3.1 Asia Pacific Filgrastim Market by Drug Type
      • 6.3.1.1 Asia Pacific Biosimilar Market by Country
      • 6.3.1.2 Asia Pacific Biologic Market by Country
    • 6.3.2 Asia Pacific Filgrastim Market by Indication
      • 6.3.2.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
      • 6.3.2.2 Asia Pacific Chronic Neutropenia Market by Country
      • 6.3.2.3 Asia Pacific Other Indications Market by Country
    • 6.3.3 Asia Pacific Filgrastim Market by Distribution Channel
      • 6.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
      • 6.3.3.2 Asia Pacific Retail Pharmacies Market by Country
      • 6.3.3.3 Asia Pacific Online Pharmacies Market by Country
    • 6.3.4 Asia Pacific Filgrastim Market by Country
      • 6.3.4.1 China Filgrastim Market
        • 6.3.4.1.1 China Filgrastim Market by Drug Type
        • 6.3.4.1.2 China Filgrastim Market by Indication
        • 6.3.4.1.3 China Filgrastim Market by Distribution Channel
      • 6.3.4.2 Japan Filgrastim Market
        • 6.3.4.2.1 Japan Filgrastim Market by Drug Type
        • 6.3.4.2.2 Japan Filgrastim Market by Indication
        • 6.3.4.2.3 Japan Filgrastim Market by Distribution Channel
      • 6.3.4.3 India Filgrastim Market
        • 6.3.4.3.1 India Filgrastim Market by Drug Type
        • 6.3.4.3.2 India Filgrastim Market by Indication
        • 6.3.4.3.3 India Filgrastim Market by Distribution Channel
      • 6.3.4.4 South Korea Filgrastim Market
        • 6.3.4.4.1 South Korea Filgrastim Market by Drug Type
        • 6.3.4.4.2 South Korea Filgrastim Market by Indication
        • 6.3.4.4.3 South Korea Filgrastim Market by Distribution Channel
      • 6.3.4.5 Singapore Filgrastim Market
        • 6.3.4.5.1 Singapore Filgrastim Market by Drug Type
        • 6.3.4.5.2 Singapore Filgrastim Market by Indication
        • 6.3.4.5.3 Singapore Filgrastim Market by Distribution Channel
      • 6.3.4.6 Malaysia Filgrastim Market
        • 6.3.4.6.1 Malaysia Filgrastim Market by Drug Type
        • 6.3.4.6.2 Malaysia Filgrastim Market by Indication
        • 6.3.4.6.3 Malaysia Filgrastim Market by Distribution Channel
      • 6.3.4.7 Rest of Asia Pacific Filgrastim Market
        • 6.3.4.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
        • 6.3.4.7.2 Rest of Asia Pacific Filgrastim Market by Indication
        • 6.3.4.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel
  • 6.4 LAMEA Filgrastim Market
    • 6.4.1 LAMEA Filgrastim Market by Drug Type
      • 6.4.1.1 LAMEA Biosimilar Market by Country
      • 6.4.1.2 LAMEA Biologic Market by Country
    • 6.4.2 LAMEA Filgrastim Market by Indication
      • 6.4.2.1 LAMEA Chemotherapy induced Neutropenia Market by Country
      • 6.4.2.2 LAMEA Chronic Neutropenia Market by Country
      • 6.4.2.3 LAMEA Other Indications Market by Country
    • 6.4.3 LAMEA Filgrastim Market by Distribution Channel
      • 6.4.3.1 LAMEA Hospital Pharmacies Market by Country
      • 6.4.3.2 LAMEA Retail Pharmacies Market by Country
      • 6.4.3.3 LAMEA Online Pharmacies Market by Country
    • 6.4.4 LAMEA Filgrastim Market by Country
      • 6.4.4.1 Brazil Filgrastim Market
        • 6.4.4.1.1 Brazil Filgrastim Market by Drug Type
        • 6.4.4.1.2 Brazil Filgrastim Market by Indication
        • 6.4.4.1.3 Brazil Filgrastim Market by Distribution Channel
      • 6.4.4.2 Argentina Filgrastim Market
        • 6.4.4.2.1 Argentina Filgrastim Market by Drug Type
        • 6.4.4.2.2 Argentina Filgrastim Market by Indication
        • 6.4.4.2.3 Argentina Filgrastim Market by Distribution Channel
      • 6.4.4.3 UAE Filgrastim Market
        • 6.4.4.3.1 UAE Filgrastim Market by Drug Type
        • 6.4.4.3.2 UAE Filgrastim Market by Indication
        • 6.4.4.3.3 UAE Filgrastim Market by Distribution Channel
      • 6.4.4.4 Saudi Arabia Filgrastim Market
        • 6.4.4.4.1 Saudi Arabia Filgrastim Market by Drug Type
        • 6.4.4.4.2 Saudi Arabia Filgrastim Market by Indication
        • 6.4.4.4.3 Saudi Arabia Filgrastim Market by Distribution Channel
      • 6.4.4.5 South Africa Filgrastim Market
        • 6.4.4.5.1 South Africa Filgrastim Market by Drug Type
        • 6.4.4.5.2 South Africa Filgrastim Market by Indication
        • 6.4.4.5.3 South Africa Filgrastim Market by Distribution Channel
      • 6.4.4.6 Nigeria Filgrastim Market
        • 6.4.4.6.1 Nigeria Filgrastim Market by Drug Type
        • 6.4.4.6.2 Nigeria Filgrastim Market by Indication
        • 6.4.4.6.3 Nigeria Filgrastim Market by Distribution Channel
      • 6.4.4.7 Rest of LAMEA Filgrastim Market
        • 6.4.4.7.1 Rest of LAMEA Filgrastim Market by Drug Type
        • 6.4.4.7.2 Rest of LAMEA Filgrastim Market by Indication
        • 6.4.4.7.3 Rest of LAMEA Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Amgen, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Pfizer, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Approvals and Trials:
  • 7.4 Novartis AG
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Product Launches and Product Expansions:
  • 7.5 Dr. Reddy's Laboratories Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Partnerships, Collaborations, and Agreements:
      • 7.5.5.2 Product Launches and Product Expansions:
  • 7.6 Teva Pharmaceutical Industries Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expenses
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Approvals and Trials:
  • 7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Partnerships, Collaborations, and Agreements:
  • 7.8 Cadila Healthcare Ltd. (Zydus Cadila)
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Apotex, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Product Launches and Product Expansions:
  • 7.10 Toksoz Group
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 Global Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 2 Global Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 3 Global Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 4 Global Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 5 Global Biosimilar Market by Region, 2017 - 2020, USD Million
  • TABLE 6 Global Biosimilar Market by Region, 2021 - 2027, USD Million
  • TABLE 7 Global Biologic Market by Region, 2017 - 2020, USD Million
  • TABLE 8 Global Biologic Market by Region, 2021 - 2027, USD Million
  • TABLE 9 Global Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 10 Global Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 11 Global Chemotherapy induced Neutropenia Market by Region, 2017 - 2020, USD Million
  • TABLE 12 Global Chemotherapy induced Neutropenia Market by Region, 2021 - 2027, USD Million
  • TABLE 13 Global Chronic Neutropenia Market by Region, 2017 - 2020, USD Million
  • TABLE 14 Global Chronic Neutropenia Market by Region, 2021 - 2027, USD Million
  • TABLE 15 Global Other Indications Market by Region, 2017 - 2020, USD Million
  • TABLE 16 Global Other Indications Market by Region, 2021 - 2027, USD Million
  • TABLE 17 Global Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 18 Global Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 19 Global Hospital Pharmacies Market by Region, 2017 - 2020, USD Million
  • TABLE 20 Global Hospital Pharmacies Market by Region, 2021 - 2027, USD Million
  • TABLE 21 Global Retail Pharmacies Market by Region, 2017 - 2020, USD Million
  • TABLE 22 Global Retail Pharmacies Market by Region, 2021 - 2027, USD Million
  • TABLE 23 Global Online Pharmacies Market by Region, 2017 - 2020, USD Million
  • TABLE 24 Global Online Pharmacies Market by Region, 2021 - 2027, USD Million
  • TABLE 25 Global Filgrastim Market by Region, 2017 - 2020, USD Million
  • TABLE 26 Global Filgrastim Market by Region, 2021 - 2027, USD Million
  • TABLE 27 North America Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 28 North America Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 29 North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 30 North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 31 North America Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 32 North America Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 33 North America Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 34 North America Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 35 North America Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 36 North America Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 37 North America Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 38 North America Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 39 North America Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 40 North America Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 41 North America Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 42 North America Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 43 North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 44 North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 45 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 46 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 47 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 48 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 49 North America Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 50 North America Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 51 North America Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 52 North America Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 53 US Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 54 US Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 55 US Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 56 US Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 57 US Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 58 US Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 59 US Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 60 US Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 61 Canada Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 62 Canada Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 63 Canada Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 64 Canada Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 65 Canada Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 66 Canada Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 67 Canada Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 68 Canada Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 69 Mexico Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 70 Mexico Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 71 Mexico Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 72 Mexico Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 73 Mexico Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 74 Mexico Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 75 Mexico Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 76 Mexico Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 77 Rest of North America Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 78 Rest of North America Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 79 Rest of North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 80 Rest of North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 81 Rest of North America Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 82 Rest of North America Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 83 Rest of North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 84 Rest of North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 85 Europe Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 86 Europe Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 87 Europe Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 88 Europe Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 89 Europe Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 90 Europe Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 91 Europe Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 92 Europe Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 93 Europe Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 94 Europe Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 95 Europe Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 96 Europe Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 97 Europe Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 98 Europe Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 99 Europe Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 100 Europe Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 101 Europe Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 102 Europe Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 103 Europe Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 104 Europe Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 105 Europe Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 106 Europe Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 107 Europe Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 108 Europe Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 109 Europe Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 110 Europe Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 111 Germany Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 112 Germany Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 113 Germany Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 114 Germany Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 115 Germany Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 116 Germany Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 117 Germany Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 118 Germany Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 119 UK Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 120 UK Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 121 UK Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 122 UK Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 123 UK Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 124 UK Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 125 UK Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 126 UK Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 127 France Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 128 France Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 129 France Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 130 France Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 131 France Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 132 France Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 133 France Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 134 France Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 135 Russia Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 136 Russia Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 137 Russia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 138 Russia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 139 Russia Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 140 Russia Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 141 Russia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 142 Russia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 143 Spain Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 144 Spain Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 145 Spain Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 146 Spain Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 147 Spain Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 148 Spain Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 149 Spain Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 150 Spain Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 151 Italy Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 152 Italy Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 153 Italy Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 154 Italy Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 155 Italy Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 156 Italy Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 157 Italy Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 158 Italy Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 159 Rest of Europe Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 160 Rest of Europe Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 161 Rest of Europe Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 162 Rest of Europe Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 163 Rest of Europe Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 164 Rest of Europe Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 165 Rest of Europe Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 166 Rest of Europe Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 167 Asia Pacific Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 168 Asia Pacific Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 169 Asia Pacific Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 170 Asia Pacific Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 171 Asia Pacific Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 172 Asia Pacific Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 173 Asia Pacific Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 174 Asia Pacific Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 175 Asia Pacific Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 176 Asia Pacific Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 177 Asia Pacific Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 178 Asia Pacific Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 179 Asia Pacific Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 180 Asia Pacific Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 181 Asia Pacific Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 182 Asia Pacific Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 183 Asia Pacific Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 184 Asia Pacific Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 185 Asia Pacific Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 186 Asia Pacific Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 187 Asia Pacific Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 188 Asia Pacific Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 189 Asia Pacific Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 190 Asia Pacific Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 191 Asia Pacific Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 192 Asia Pacific Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 193 China Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 194 China Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 195 China Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 196 China Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 197 China Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 198 China Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 199 China Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 200 China Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 201 Japan Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 202 Japan Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 203 Japan Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 204 Japan Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 205 Japan Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 206 Japan Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 207 Japan Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 208 Japan Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 209 India Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 210 India Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 211 India Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 212 India Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 213 India Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 214 India Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 215 India Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 216 India Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 217 South Korea Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 218 South Korea Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 219 South Korea Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 220 South Korea Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 221 South Korea Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 222 South Korea Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 223 South Korea Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 224 South Korea Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 225 Singapore Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 226 Singapore Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 227 Singapore Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 228 Singapore Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 229 Singapore Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 230 Singapore Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 231 Singapore Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 232 Singapore Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 233 Malaysia Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 234 Malaysia Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 235 Malaysia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 236 Malaysia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 237 Malaysia Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 238 Malaysia Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 239 Malaysia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 240 Malaysia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 241 Rest of Asia Pacific Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 242 Rest of Asia Pacific Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 243 Rest of Asia Pacific Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 244 Rest of Asia Pacific Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 245 Rest of Asia Pacific Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 246 Rest of Asia Pacific Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 247 Rest of Asia Pacific Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 248 Rest of Asia Pacific Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 249 LAMEA Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 250 LAMEA Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 251 LAMEA Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 252 LAMEA Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 253 LAMEA Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 254 LAMEA Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 255 LAMEA Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 256 LAMEA Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 257 LAMEA Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 258 LAMEA Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 259 LAMEA Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 260 LAMEA Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 261 LAMEA Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 262 LAMEA Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 263 LAMEA Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 264 LAMEA Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 265 LAMEA Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 266 LAMEA Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 267 LAMEA Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 268 LAMEA Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 269 LAMEA Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 270 LAMEA Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 271 LAMEA Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 272 LAMEA Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 273 LAMEA Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 274 LAMEA Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 275 Brazil Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 276 Brazil Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 277 Brazil Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 278 Brazil Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 279 Brazil Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 280 Brazil Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 281 Brazil Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 282 Brazil Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 283 Argentina Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 284 Argentina Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 285 Argentina Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 286 Argentina Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 287 Argentina Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 288 Argentina Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 289 Argentina Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 290 Argentina Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 291 UAE Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 292 UAE Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 293 UAE Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 294 UAE Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 295 UAE Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 296 UAE Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 297 UAE Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 298 UAE Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 299 Saudi Arabia Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 300 Saudi Arabia Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 301 Saudi Arabia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 302 Saudi Arabia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 303 Saudi Arabia Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 304 Saudi Arabia Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 305 Saudi Arabia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 306 Saudi Arabia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 307 South Africa Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 308 South Africa Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 309 South Africa Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 310 South Africa Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 311 South Africa Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 312 South Africa Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 313 South Africa Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 314 South Africa Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 315 Nigeria Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 316 Nigeria Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 317 Nigeria Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 318 Nigeria Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 319 Nigeria Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 320 Nigeria Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 321 Nigeria Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 322 Nigeria Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 323 Rest of LAMEA Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 324 Rest of LAMEA Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 325 Rest of LAMEA Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 326 Rest of LAMEA Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 327 Rest of LAMEA Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 328 Rest of LAMEA Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 329 Rest of LAMEA Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 330 Rest of LAMEA Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 331 Key Information - Abbott Laboratories
  • TABLE 332 Key Information - Amgen, Inc.
  • TABLE 333 Key Information - Pfizer, Inc.
  • TABLE 334 Key Information - Novartis AG
  • TABLE 335 key information - Dr. Reddy's Laboratories Ltd.
  • TABLE 336 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 337 Key Information - Kyowa Kirin Co., Ltd.
  • TABLE 338 Key Information - Cadila Healthcare Ltd.
  • TABLE 339 Key Information - Apotex, Inc.
  • TABLE 340 Key Information - Toksoz Group

List of Figures

  • FIG 1 Methodology for the research